Antineoplásicos/uso terapéutico; Inhibidores Enzimáticos/uso terapéutico; Receptores ErbB/metabolismo; Oseltamivir/uso terapéutico; Páncreas/efectos de los fármacos; Neoplasias Pancreáticas/tratamiento farmacológico; Transducción de Señal/efectos de los fármacos; Animales; Línea Celular Tumoral; Factor de Crecimiento Epidérmico/metabolismo; Humanos; Masculino; Metaloproteinasa 9 de la Matriz/metabolismo; Ratones; Células 3T3 NIH; Metástasis de la Neoplasia/prevención & control; Neuraminidasa/metabolismo; Páncreas/metabolismo; Páncreas/patología; Neoplasias Pancreáticas/metabolismo; Neoplasias Pancreáticas/patología

0EGF; 4-MUNANA; Akt; Cγ; FGF; IC(50); MMP; Matrix metalloproteinase-9; NGF; Neu1; Neuraminidase-1; PDGF; Pancreatic cancer; RAG2; RTKs; SMAD2; STAT1; TLR; TOLL-like receptor; VEGF; [2'-(4-methylyumbelliferyl)-α-D-N-acetylneuraminic acid]; combining recombinase activating gene-2; common cytokine receptor γ chain; epidermal growth factor; fibroblast growth factor; mammalian neuraminidase-1; matrix metalloproteinase; mothers against decapentaplegic homolog-2 signal transducer and transcriptional modulator; nerve growth factor; platelet-derived growth factor; protein kinase B (PKB) a serine/threonine-specific protein kinase; receptor tyrosine kinases; signal transducer and activator of transcription-1, 91kDa; the concentration of a drug that is required for 50% inhibition in vitro; vascular endothelial growth factor